CoChat

Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases

Open access
Lo, Chih Hung, Zeng, Jialiu · 2023 · Translational Neurodegeneration

The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.

Abstract

Lysosomal acidification dysfunction has been implicated as a key driving factor in the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Multiple genetic factors have been linked to lysosomal de-acidification through impairing the vacuolar-type ATPase and ion channels on the organelle membrane. Similar lysosomal abnormalities are also present in sporadic forms of neurodegeneration, although the underlying pathogenic mechanisms are unclear and remain to be investigated. Importantly, recent studies have revealed early occurrence of lysosomal acidification impairment before the onset of neurodegeneration and late-stage pathology. However, there is a lack of methods for organelle pH monitoring in vivo and a dearth of lysosome-acidifying therapeutic agents. Here, we summarize and present evidence for the notion of defective lysosomal acidification as an early indicator of neurodegeneration and urge the critical need for technological advancement in developing tools for lysosomal pH monitoring and detection both in vivo and for clinical applications. We further discuss current preclinical pharmacological agents that modulate lysosomal acidification, including small molecules and nanomedicine, and their potential clinical translation into lysosome-targeting therapies. Both timely detection of lysosomal dysfunction and development of therapeutics that restore lysosomal function represent paradigm shifts in targeting neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40035-023-00362-0

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Role of lysosomal acidification dysfunction in early neurodegenerative pathology. a Under normal physiological conditions, acidified lysosomes fuse with autophagosomes to form sufficiently acidified autolysosomes which can efficiently degrade accumulated cell debris and toxic protein aggregates. b Under pathological conditions, lysosomes with elevated pH either have no fusion with autophagosomes leading to no degradation, or fuse with autophagosomes to form poorly acidified autolysosomes which are inefficient in cellular degradation. c Poorly acidified lysosomes induce alterations from normal cellular and metabolic functions to early neurodegenerative pathology and could act as an early indicator of disease pathogenesis. d Pathogenesis of neurodegenerative diseases initiates with early pathology including increases of neuroinflammatory cytokines, activated glial cells, impaired neurotransmission, mitochondrial dysfunction, reactive oxygen species (ROS) production, and accumulation of pre-fibrillar, oligomeric toxic intrinsically disordered protein (IDP) aggregates due to inefficient cellular degradation by poorly acidified autolysosomes. e Late-stage neurodegeneration pathology includes the presence of toxic protein aggregates such as tau neurofibrillary tangles, Aβ plaques, and Lewy bodies with α-synuclein, as well as neuronal death. Schematics were created by BioRender.
Fig. 1 Role of lysosomal acidification dysfunction in early neurodegenerative pathology. a Under normal physiological conditions, acidified lysosomes fuse with autophagosomes to form sufficiently acidified autolysosomes which can efficiently degrade accumulated cell debris and toxic protein aggregates. b Under pathological conditions, lysosomes with elevated pH either have no fusion with autophagosomes leading to no degradation, or fuse with autophagosomes to form poorly acidified autolysosomes which are inefficient in cellular degradation. c Poorly acidified lysosomes induce alterations from normal cellular and metabolic functions to early neurodegenerative pathology and could act as an early indicator of disease pathogenesis. d Pathogenesis of neurodegenerative diseases initiates with early pathology including increases of neuroinflammatory cytokines, activated glial cells, impaired neurotransmission, mitochondrial dysfunction, reactive oxygen species (ROS) production, and accumulation of pre-fibrillar, oligomeric toxic intrinsically disordered protein (IDP) aggregates due to inefficient cellular degradation by poorly acidified autolysosomes. e Late-stage neurodegeneration pathology includes the presence of toxic protein aggregates such as tau neurofibrillary tangles, Aβ plaques, and Lewy bodies with α-synuclein, as well as neuronal death. Schematics were created by BioRender.CC BY · PubMed Central
Fig. 2 Strategies and methods for detecting autolysosomal dysfunction. a Detection of changes in autolysosomal acidification using fluorescent protein reporter (e.g., mRFP-eGFP-LC3) and small-molecule pH probes (e.g., Lysosensor Yellow/Blue). b Monitoring of autolysosomal acidification in vivo through intravital imaging of the reporter mouse brain using multiphoton microscopy. c Positron emission tomography (PET) imaging using protein markers that correlate with autolysosomal dysfunction to detect early onset of neurodegeneration in patients. d Blood- and CSF-based biomarkers that are associated with autolysosomal dysfunction, such as cathepsin level/activity and other molecular signatures obtained from CNS-derived exosomes, are potential early indicators of neurodegeneration. Schematics were created by BioRender.
Fig. 2 Strategies and methods for detecting autolysosomal dysfunction. a Detection of changes in autolysosomal acidification using fluorescent protein reporter (e.g., mRFP-eGFP-LC3) and small-molecule pH probes (e.g., Lysosensor Yellow/Blue). b Monitoring of autolysosomal acidification in vivo through intravital imaging of the reporter mouse brain using multiphoton microscopy. c Positron emission tomography (PET) imaging using protein markers that correlate with autolysosomal dysfunction to detect early onset of neurodegeneration in patients. d Blood- and CSF-based biomarkers that are associated with autolysosomal dysfunction, such as cathepsin level/activity and other molecular signatures obtained from CNS-derived exosomes, are potential early indicators of neurodegeneration. Schematics were created by BioRender.CC BY · PubMed Central
Fig. 3 Lysosomal acidification-modulating agents. a Schematic representation of lysosomal acidification modulation by small molecules and lysosome-targeting nanomedicine. b C381 and EN6 activate V-ATPase to promote the proton-pumping capacity of the enzyme complex. c Cyclic adenosine monophosphate (cAMP, regulator of lysosomal pH) and NKH-477 (adenylyl cyclase activator) increase the intracellular content of cAMP, which is essential for maintaining lysosomal acidification. d Targeting ion channels, such as activating TRPML1 by SF-22 and inhibiting TPC2 by tetrandrine, allows for a balance of ions in the lysosome lumen to maintain lysosomal acidification. e Curcumin analog C1 and PF11 activate transcription factor EB (TFEB) and increase its nuclear localization to enable the expression of lysosomal components and enhance luminal acidification. f OSI-027 and PP242 acidify lysosomes by inhibiting mTOR signaling. g Lysosome-targeting nanoparticles (NPs) or nucleolipid nanoemulsions (NL-NEs) formed by various chemical compositions. Compositions of the NPs or NL-NEs shown are based on the most widely used formulations that have demonstrated significant efficacy, although they are modulable and can be further optimized to serve different purposes. The NPs or NL-NEs have a size of 100–200 nm, polydispersity (PDI) of 0.1–0.2 (which indicates a monodisperse population), and abilities to cross the blood-brain barrier (BBB) at 5%–15% of injected dose and lower lysosomal pH by 0.5–3.0 pH units. *The reported values for BBB penetration are only applicable to PLGA NPs and AcNPs; PaNPs and acidic NL-NEs have not been characterized. PLGA NPs, Poly(lactic-co-glycolic acid) NPs; AcNPs, Acidic NPs; PaNPs, Photo-activated NPs; Acidic NL-NEs, Acidic nucleolipid nanoemulsions; LA, Lactic acid; GA, Glycolic acid; TFSA, Tetrafluorosuccinic acid; SA, Succinic acid. Schematics were created by BioRender and chemical structures were drawn by ChemDraw.
Fig. 3 Lysosomal acidification-modulating agents. a Schematic representation of lysosomal acidification modulation by small molecules and lysosome-targeting nanomedicine. b C381 and EN6 activate V-ATPase to promote the proton-pumping capacity of the enzyme complex. c Cyclic adenosine monophosphate (cAMP, regulator of lysosomal pH) and NKH-477 (adenylyl cyclase activator) increase the intracellular content of cAMP, which is essential for maintaining lysosomal acidification. d Targeting ion channels, such as activating TRPML1 by SF-22 and inhibiting TPC2 by tetrandrine, allows for a balance of ions in the lysosome lumen to maintain lysosomal acidification. e Curcumin analog C1 and PF11 activate transcription factor EB (TFEB) and increase its nuclear localization to enable the expression of lysosomal components and enhance luminal acidification. f OSI-027 and PP242 acidify lysosomes by inhibiting mTOR signaling. g Lysosome-targeting nanoparticles (NPs) or nucleolipid nanoemulsions (NL-NEs) formed by various chemical compositions. Compositions of the NPs or NL-NEs shown are based on the most widely used formulations that have demonstrated significant efficacy, although they are modulable and can be further optimized to serve different purposes. The NPs or NL-NEs have a size of 100–200 nm, polydispersity (PDI) of 0.1–0.2 (which indicates a monodisperse population), and abilities to cross the blood-brain barrier (BBB) at 5%–15% of injected dose and lower lysosomal pH by 0.5–3.0 pH units. *The reported values for BBB penetration are only applicable to PLGA NPs and AcNPs; PaNPs and acidic NL-NEs have not been characterized. PLGA NPs, Poly(lactic-co-glycolic acid) NPs; AcNPs, Acidic NPs; PaNPs, Photo-activated NPs; Acidic NL-NEs, Acidic nucleolipid nanoemulsions; LA, Lactic acid; GA, Glycolic acid; TFSA, Tetrafluorosuccinic acid; SA, Succinic acid. Schematics were created by BioRender and chemical structures were drawn by ChemDraw.CC BY · PubMed Central
Fig. 4 Mechanisms of action of lysosome-targeting nanoparticles (NPs) and nanocarriers. a Poly(lactic-co-glycolic acid) (PLGA) NPs will dissociate into their respective component acids, lactic acid (pKa 3.86) and glycolic acid (pKa 3.83), under mildly acidic conditions and directly acidify lysosomes. b Acidic NPs (AcNPs) formed by poly(ethylene tetrafluorosuccinate-co-succinate) will dissociate into their respective component acids, tetrafluorosuccinic acid (pKa 1.63) and succinic acid (pKa 4.20), under mildly acidic conditions and directly acidify lysosomes. c PaNPs are activated upon stimulation by UV light (~ 365 nm), enabling a spatiotemporal control of lysosomal pH by releasing succinic acid. d Acidic nucleolipid nanoemulsions (NL-NEs) are designed to release succinic acid upon enzymatic degradation. Mechanisms of action illustrated are based on the theoretical breakdown of the formed NPs and NL-NEs into their respective component acids. ‘x’ and ‘y’ represent the percentage of each component acid used in the synthesis process. Schematics were created by BioRender and chemical structures were drawn by ChemDraw.
Fig. 4 Mechanisms of action of lysosome-targeting nanoparticles (NPs) and nanocarriers. a Poly(lactic-co-glycolic acid) (PLGA) NPs will dissociate into their respective component acids, lactic acid (pKa 3.86) and glycolic acid (pKa 3.83), under mildly acidic conditions and directly acidify lysosomes. b Acidic NPs (AcNPs) formed by poly(ethylene tetrafluorosuccinate-co-succinate) will dissociate into their respective component acids, tetrafluorosuccinic acid (pKa 1.63) and succinic acid (pKa 4.20), under mildly acidic conditions and directly acidify lysosomes. c PaNPs are activated upon stimulation by UV light (~ 365 nm), enabling a spatiotemporal control of lysosomal pH by releasing succinic acid. d Acidic nucleolipid nanoemulsions (NL-NEs) are designed to release succinic acid upon enzymatic degradation. Mechanisms of action illustrated are based on the theoretical breakdown of the formed NPs and NL-NEs into their respective component acids. ‘x’ and ‘y’ represent the percentage of each component acid used in the synthesis process. Schematics were created by BioRender and chemical structures were drawn by ChemDraw.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 103 references

Cited by

See all 132

Metadata

Authors
Lo, C. H., & Zeng, J.
Affiliations
Nanyang Technological University (SG)
Corresponding author
  • Lo, Chih Hung
  • Zeng, Jialiu
Venue
Translational Neurodegeneration
Published
2023-06-08
Volume
12
Issue
1
Pages
29-29
ISSN
2047-9158 (ISSN-L)
OpenAlex
W4379740904
Cited by
117
References
102
Citations by year
2026: 39 · 2025: 40 · 2024: 27 · 2023: 11
FWCI
4.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DR-NTU (Nanyang Technological University) (submittedVersion, cc-by)
Funders
  • Lee Kong Chian School of Medicine, Nanyang Technological University (Dean's Postdoctoral Fellowship (Grant/Award Number: 021207-00001))
  • Momental Foundation (Mistletoe Research Fellowship (Grant Award Number 022522-00001))
  • Nanyang Technological University (Presidential Postdoctoral Fellowship (Grant/Award Number: 021229-00001))
  • National Medical Research Council (Open Fund Young Investigator Research Grant (OF-YIRG) (Grant Award Number MOH-001147))
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
lysosomal acidification, lysosomal dysfunction, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, vacuolar ATPase, early biomarkers, nanomedicine
MeSH terms
Alzheimer Disease, Humans, Hydrogen-Ion Concentration, Lysosomes, Prognosis, Neurodegenerative Diseases, Vacuolar Proton-Translocating ATPases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases. https://app.cochat.ai/papers/10.1186/s40035-023-00362-0
The paper
Lo, C. H., & Zeng, J. (2023). Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases. Translational Neurodegeneration. https://doi.org/10.1186/s40035-023-00362-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.